- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | Day One Biopharmaceuticals, Inc.: Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 | 5 | GlobeNewswire (USA) | ||
| 10.10. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.08. | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | 8 | Seeking Alpha | ||
| 05.08. | Day One Biopharmaceuticals: Umsatzwachstum bei OJEMDA hält an, während die Entwicklungspipeline voranschreitet | 19 | Investing.com Deutsch | ||
| 05.08. | Day One Biopharmaceuticals Non-GAAP EPS of -$0.29 beats by $0.05, revenue of $33.91M misses by $0.99M | 16 | Seeking Alpha | ||
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 05.08. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 05.08. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | Day One Biopharmaceuticals, Inc.: Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 | 3 | GlobeNewswire (USA) | ||
| 23.06. | TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN) | 7 | Insider Monkey | ||
| 10.06. | Day One Biopharmaceuticals, Inc.: Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development | 5 | GlobeNewswire (USA) | ||
| 03.06. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.05. | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress | 708 | GlobeNewswire (Europe) | OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,60 | +0,44 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CUREVAC | 4,572 | -1,08 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| AMGEN | 259,70 | +0,78 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 7,338 | +0,60 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| BIOGEN | 134,75 | +0,60 % | Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus! | © Foto: Jonathan Brady/PA Wire/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 56,00 | +0,90 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| MAINZ BIOMED | 1,460 | -2,67 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,520 | +1,53 % | Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences | ||
| INTELLIA THERAPEUTICS | 11,110 | +0,09 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 78,50 | +0,64 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| BIOCRYST PHARMACEUTICALS | 6,504 | +2,30 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 21,140 | +1,54 % | A Peek at Sarepta Therapeutics' Future Earnings | ||
| BIOMARIN PHARMACEUTICAL | 44,770 | -3,58 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| EXELIXIS | 34,010 | +1,40 % | Exelixis Q2 2025: Cabozantinib-Franchise wächst um 19 %, Markteinführung bei NET gewinnt an Fahrt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,020 | -0,74 % | Cathie Wood's ARK ETFs buy DraftKings, Pacific Biosciences stock |
Das Unternehmen DAY ONE BIOPHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,390 (+5,54 %) liegt der Kurs bei 7,435 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.